Premium
One‐week versus two‐week furazolidone‐based quadruple therapy as the first‐line treatment for Helicobacter pylori infection in Iran
Author(s) -
Daghaghzadeh Hamed,
Emami Mohammad Hasan,
Karimi Somayeh,
Raeisi Mostafa
Publication year - 2007
Publication title -
journal of gastroenterology and hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.214
H-Index - 130
eISSN - 1440-1746
pISSN - 0815-9319
DOI - 10.1111/j.1440-1746.2007.05029.x
Subject(s) - furazolidone , medicine , helicobacter pylori , omeprazole , amoxicillin , gastroenterology , intention to treat analysis , randomized controlled trial , antibiotics , microbiology and biotechnology , biology
Background and Aim: Furazolidone‐based regimens for the eradication of Helicobacter pylori are low cost and effective although less tolerable. Our aim was to compare the efficacy and compliance of 1‐week furazolidone‐based quadruple therapy (furazolidone, amoxicillin, bismuth subcitrate, omeprazole; FABO) with 2‐week quadruple therapy using the same drugs. Methods: One hundred and fifty‐six consecutive patients with H. pylori related diseases were enrolled in our study. The patients were randomized into two groups of FABO1 and FABO2 groups receiving, 1 or 2 weeks' quadruple H. pylori eradication therapies, respectively, as follows: furazolidone (200 mg twice daily), amoxicillin (1 g twice daily), bismuth (240 mg twice daily) and omeprazole (20 mg twice daily). The χ 2 test was used to compare the efficacy of the therapies. Results: The per‐protocol eradication rate in FABO1 and FABO2 groups were 56/66 (84.8%) and 57/69 (82.6%), respectively. The intention‐to‐treat eradication rate was 56/78 (71.8%) in FABO1 group and 57/78 (73.1%) in FABO2 group. There was not any significant statistical difference between two groups. A significant decrease in compliance in FABO2 group was seen. Conclusion: This is an encouraging report showing a therapy with possible success in decreasing the duration of H. pylori infection as well as reaching the eradication rate of 80%.